Scientists Develop Universal Pneumonia Vaccine

A team of British scientists has made a crucial advancement in the quest for a universal pneumococcal vaccine. Their innovative approach replaces traditional capsular polysaccharides with proteins, leveraging reverse vaccinology to identify potential vaccine candidates directly from bacterial genomes. This method bypasses the need for culturing and purifying components, streamlining vaccine development.

The scientists analyzed the Streptococcus pneumoniae genome, pinpointing genes encoding surface proteins with low human similarity and the ability to elicit robust immunity. Three candidate proteins, Z, P, and Y, were selected and formulated into an experimental vaccine, ZPY-CpG-Ch, along with immune boosters.

Laboratory tests on mice showed that the ZPY-CpG-Ch vaccine provided 80-100% survival against lethal doses of serotype 1, comparable to current vaccines. Crucially, it also offered protection against non-vaccine serotypes, a significant improvement over existing vaccines that can lead to serotype replacement.

While these results are preliminary and tested against a limited number of serotypes, this work represents a promising step toward a vaccine that could protect against all forms of pneumococcal disease, a major cause of pneumonia, meningitis, and sepsis.